PayPal and REGENXBIO Face Class Action Lawsuits Over Misleading Guidance

Bragar Eagel & Squire has announced the filing of class action lawsuits against two major publicly traded companies—PayPal Holdings ($PYPL) and REGENXBIO Inc. ($RGNX)—citing allegations of investor deception. The lawsuits center on allegedly misleading corporate disclosures: PayPal stands accused of providing false revenue projections and unachievable 2027 targets, while REGENXBIO faces claims of concealing critical safety concerns related to its flagship gene therapy candidate. Both companies experienced significant stock price deterioration following damaging quarterly results and regulatory developments, prompting legal action on behalf of institutional and retail investors.

Key Details of the Allegations

The PayPal litigation stems from disappointing fourth-quarter 2025 earnings results that exposed a substantial gap between management's publicly stated guidance and actual financial performance. Following the company's earnings announcement, PayPal's stock declined approximately 20%, reflecting investor frustration over unmet expectations. The lawsuit alleges that company executives provided revenue projections and articulated 2027 financial targets that were not supported by underlying business fundamentals, constituting a material misrepresentation to the investing public.

In a parallel action, REGENXBIO faces separate claims regarding its investigational gene therapy RGX-111. According to the lawsuit allegations, the company allegedly concealed or downplayed significant safety concerns associated with the therapy's clinical development. These claims became acutely relevant when the FDA issued a clinical hold on RGX-111, citing a tumor that developed in a trial participant. The regulatory setback triggered a sharp market reaction, with REGENXBIO's stock falling 17.8% following the announcement.

Key metrics from the litigation announcements:

• PayPal stock decline: ~20% post-earnings
• REGENXBIO stock decline: 17.8% following FDA clinical hold
• Trigger event for REGENXBIO: Tumor identified in RGX-111 trial participant
• Trigger event for PayPal: Q4 2025 earnings miss and unachievable 2027 guidance

Market Context and Industry Implications

These lawsuits reflect broader concerns about corporate governance and disclosure accuracy that have gained prominence across multiple sectors. PayPal, a digital payments giant with substantial institutional ownership, operates in an increasingly competitive landscape where guidance credibility is paramount. The company faces rivalry from traditional financial institutions, fintech upstarts, and payment processors including Block Inc. ($SQ) and Stripe, making accurate forward guidance essential to maintaining investor confidence.

The situation underscores persistent challenges in the financial services sector regarding earnings predictability. Payment processors and financial technology firms typically face elevated scrutiny from investors regarding guidance quality, particularly when macroeconomic headwinds or changing consumer behavior patterns could impact revenue trajectories. PayPal's 20% decline signals that the market views the guidance miss as sufficiently severe to warrant a material revaluation of the company's near-term prospects.

For REGENXBIO, the litigation reflects heightened sensitivity within the biotechnology sector regarding safety disclosures in clinical development programs. Gene therapy represents a frontier area of medical innovation, but also carries elevated clinical risk. Regulatory bodies, including the FDA, have demonstrated willingness to pause development programs when safety signals emerge, as evidenced by the RGX-111 clinical hold. Investors have become increasingly attuned to the adequacy of safety disclosure in biotech filings, particularly for therapies targeting serious genetic conditions where the risk-benefit calculus is carefully scrutinized.

The biotech sector has experienced elevated scrutiny of clinical trial transparency following multiple instances where safety concerns emerged post-announcement. Companies in this space must now maintain rigorous disclosure standards regarding adverse events, trial participant outcomes, and regulatory interactions—or face significant market penalties and potential litigation.

Investor Implications and Legal Outlook

For shareholders in PayPal and REGENXBIO, these lawsuits represent an attempt to recover losses stemming from what plaintiffs characterize as misleading corporate statements. Class action litigation typically seeks damages equal to the difference between the inflated stock price and the lower price following the corrective disclosure. With PayPal's 20% decline and REGENXBIO's 17.8% drop, affected investors face material losses that litigation may partially offset, though legal recovery is uncertain and often involves extended timeframes.

The lawsuits also carry broader implications for corporate governance. Companies face pressure to calibrate forward guidance conservatively, particularly in sectors where execution risk is elevated or market conditions are uncertain. Overly optimistic guidance, even if made in good faith, creates litigation exposure when actual results miss targets. This dynamic may lead to more conservative management outlooks and potentially lower growth expectations priced into equities.

For PayPal, the litigation adds to broader challenges facing the payment processing ecosystem. The company must navigate slowing digital transaction growth in mature markets, intensifying competition, and regulatory scrutiny of fintech platforms. Restoring investor confidence in management guidance will be critical to recovery.

For REGENXBIO, the clinical hold on RGX-111 represents a setback for a pipeline-dependent company. The litigation amplifies pressure on remaining pipeline assets to demonstrate clinical progress and safety. Gene therapy companies must now anticipate rigorous litigation risk when safety signals emerge, incentivizing transparent communication with regulators and investors throughout clinical development.

The lawsuits underscore that institutional and retail investors increasingly hold management accountable for disclosure accuracy through coordinated legal action. Class actions serve as a market mechanism to penalize corporate misrepresentation and incentivize improved disclosure practices. Companies across sectors should view these developments as reinforcement of the critical importance of accurate, conservative guidance and comprehensive safety disclosure in clinical and regulatory contexts.

Bragar Eagel & Squire's announcement encourages affected investors to participate in the litigation process, though the ultimate outcomes remain subject to discovery, motion practice, and potential settlement negotiations. The cases will likely proceed through federal courts over an extended period, with resolution potentially years away.